Catalyst Pharmaceuticals Announces Topline Results From Two-Part Phase 1 Clinical Study Of Vamorolone In Healthy Adult Volunteers

The study demonstrated balanced corticosteroid activity with expected cortisol suppression and no evidence of significant immunosuppressive activity at clinical doses.